C12N 2770/32071
Demonstrated in vivo effect
C12N2770/32071 (Demonstrated in vivo effect) appears on 7 US grants and 10 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 10
- Assignees
- 9
- Inventors
- 17
- Latest grant
- 11 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 1 | 0 |
| 2021 | 0 | 3 |
| 2022 | 1 | 1 |
| 2023 | 3 | 2 |
| 2024 | 0 | 3 |
| 2025 | 2 | 0 |
By publication year.
Recent patents
- Pharmaceutical composition containing stabilized nucleic acid adjuvant11 Nov 2025US 12,465,644 B2Sml Biopharm Co., Ltd.
- Cancer immunotherapy using virus particles8 Jul 2025US 12,350,326 B2Case Western Reserve University
- Cancer immunotherapy using virus particles22 Aug 2023US 11,730,803 B2Case Western Reserve University
- Cancer immunotherapy using virus particles4 Apr 2023US 11,617,787 B2Case Western Reserve University
- Triple vaccine against avibacterium paragallinarum and avian encephalomyelitis virus and fowl pox virus3 Jan 2023US 11,541,115 B2
- Compounds, compositions, and methods of using thereof7 Nov 2024US 2024/0366518 A1ElevateBio Technologies, Inc.
- Compounds, compositions, and methods of using thereof30 May 2024US 2024/0173267 A1Oncorus, Inc.
- Cancer immunotherapy using virus particles25 Jan 2024US 2024/0024452 A1Case Western Reserve University
- Encapsulated rna replicons and methods of use28 Dec 2023US 2023/0416308 A1Oncorus, Inc.
- Cancer immunotherapy using virus particles26 Jan 2023US 2023/0024508 A1Case Western Reserve University
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.